The Heroic Dose of Psychedelics, According to Johns Hopkins

In this Big Think talk, Matthew Johnson, a professor of psychiatry at Johns Hopkins who has led clinical psilocybin research there, explains what researchers mean by the "heroic dose," a term coined by writer Terence McKenna for the higher end of psilocybin dosing used in therapeutic trials. He places that choice inside a longer arc: a promising start to psychedelic science in the 1950s, a near-total shutdown once the drugs collided with 1960s counterculture, and the cautious clinical revival now underway. Johnson also describes what a supervised psilocybin session at Johns Hopkins involves and the ethical guardrails he says the work demands.

Why psychedelics, why now

Johnson frames the current research wave against what he calls a stagnating mental health field, in which a large share of people treated with standard antidepressants do not see benefit. In his account, psychedelics stand out among drug classes because many people describe a single experience as having a lasting effect on the course of their life. That is a clinician's characterization, not a settled finding, and Psylopedia treats psychedelic-assisted therapy as an active area of investigation, not an approved treatment.

A history of promise, backlash, and revival

Johnson traces organized psychedelic science to the 1950s, roughly a decade after Albert Hofmann identified LSD's psychoactive properties. He credits the Spring Grove group in Maryland and Abram Hoffer and Humphry Osmond in Saskatchewan with developing much of what is now called psychedelic therapy, alongside uneven safeguards and some unethical research. Timothy Leary's firing from Harvard tied psychedelics to the counterculture; society was, in Johnson's telling, effectively traumatized, and research halted for decades before today's more medically focused revival.

What "heroic dose" actually means

Johnson's own therapeutic research has centered on psilocybin, the compound in psilocybin mushrooms. In his trials, patients typically receive 30 to 40 milligrams, the range McKenna repeatedly called the heroic dose: a microdose at one end, a recreational dose in between, the heroic dose well past both.

Inside a supervised session

Participants spend several hours across earlier preparation meetings, building rapport with the clinical team before the dosing day. Johnson says set and setting shapes every drug experience but matters especially for psychedelics: a warm, welcoming context tends to produce more meaningful reactions. During the session, participants lie down wearing eyeshades and headphones playing music, meant to move attention away from ordinary analytical thought. "We really just encourage them to trust, let go, and be open," Johnson says, describing "let go" as releasing preconceived notions of the experience rather than trying to control it.

The range of what people report

At a high enough dose, Johnson says, something significant reliably happens, though its character is unpredictable, spanning expansive mystical-type experiences, a sense of soaring or universal truths revealed, to frightening states some call a bad trip, including a felt sense of dying. He describes this as a substantial disruption to a person's ordinary sense of reality and self, closer to the kind of dissolution Psylopedia covers under ego dissolution than a mild mood shift. On physiological risk, he says these substances have comparatively little measured effect on heart rate or blood pressure: "Compared to other drug classes, psychedelics are really robustly safe at the physiological level," a claim describing acute measures in a supervised setting, not the full risk picture of unsupervised use.

Integration and the limits of the therapy

Afterward, integration sessions unpack the themes that came up. Johnson describes "duh moments," in which people feel, viscerally, something they already understood intellectually, such as cancer patients recognizing their illness had not killed them yet and that they were adding to their own suffering by how they related to it. Some participants, he says, describe a single six-hour session as comparable to roughly a thousand hours of talk therapy, a subjective comparison, not a measured equivalence.

Johnson calls psychedelic therapy an unusually intimate intervention, "ripe for abuses" without firm safeguards, and argues for strict clinical boundaries, including limits on therapeutic touch. He warns against a "guru complex," the temptation to answer a participant's metaphysical questions rather than staying silent. He also suggests the research may eventually clarify what different psychiatric disorders share, framing many as variations on a narrowed mental and behavioral repertoire that psychedelics, done well, may help loosen: a research direction, not a demonstrated mechanism.

Key takeaways

• ●Johnson describes the "heroic dose" as roughly 30 to 40 milligrams of psilocybin, a term coined by Terence McKenna and used in his Johns Hopkins clinical trials.
• ●He frames psychedelic research as a response to a mental health field where many people do not respond to standard antidepressants.
• ●Organized psychedelic research began in the 1950s (Spring Grove in Maryland; Hoffer and Osmond in Saskatchewan) before 1960s counterculture backlash halted it for decades.
• ●Johns Hopkins sessions involve multiple preparation meetings; setting, eyeshades, music, and guide support are treated as central to the experience.
• ●High-dose sessions reliably produce a major, unpredictable shift in experience, from expansive to frightening, with little acute effect on heart rate or blood pressure.
• ●Integration afterward unpacks themes; Johnson describes "duh moments" where participants feel something they already knew intellectually.
• ●The intimacy of this work demands strict clinical boundaries, Johnson says, warning specifically against a "guru complex."
• ●Psychedelic-assisted therapy remains investigational; the claims here reflect one clinician-researcher's account, not an approved protocol.